Danielle Bucco

Articles

Weiss Weighs In on Challenges in NSCLC

March 30th 2018

Jared Weiss, MD, shares his insight on challenges in the field of non–small cell lung cancer, such as optimal sequencing.

Genetic Testing Helps Guide Treatment in Prostate Cancer

March 28th 2018

Veda Giri, MD, discusses the developing role of genetic testing for the screening and management of patients with prostate cancer.

Biomarker Development Critical to Continued Progress in NSCLC

March 24th 2018

Jeffrey Melson Clarke, MD, discusses the latest developments with biomarkers in NSCLC.

Brentjens Highlights BCMA, Next Steps With CAR T-Cell Therapy

March 22nd 2018

Renier J. Brentjens, MD, PhD, discusses the emergence of BCMA as a target for CAR T-cell therapy and other next steps for the field.

Goy Lends Insight on Acalabrutinib and Ibrutinib in MCL

March 22nd 2018

Andre Goy, MD, discusses the excitement surrounding acalabrutinib, as well as emerging ibrutinib combination strategies for the treatment of patients with mantle cell lymphoma.

Novel Therapies Bring Hope in Biliary Tract Cancers

March 21st 2018

John Gordan, MD, PhD, discusses the challenges of treating patients with biliary tract cancers and novel therapies in development.

CLL Expert Explains Latest Treatment Developments in the Field

March 21st 2018

Neil E. Kay, MD, discusses the available options and sequencing challenges for patients with relapsed/refractory chronic lymphocytic leukemia, as well as next steps for advancing outcomes for this patient population.

Klopp Comments on Optimizing Chemoradiation in Endometrial Cancer

March 20th 2018

Ann H. Klopp, MD, PhD, discusses optimizing the use of chemoradiation and the future of the treatment landscape in endometrial cancer.

Venook Highlights Impact of IDEA Trial in Colon Cancer

March 19th 2018

Alan P. Venook, MD, discusses the significance of the findings of the international IDEA study investigating doses of FOLFOX for patients with colon cancer.

Guidelines Clarify Management of Immune-Related AEs in Lung Cancer

March 14th 2018

Heather Greene, NP, discusses the safety profile for patients with lung cancer receiving immunotherapy, and the importance for reporting immune-related adverse events.

Fostamatinib Active in Chronic Immune Thrombocytopenic Purpura

March 8th 2018

Fostamatinib resulted in clinically meaningful, ongoing platelet responses and a low rate of bleeding events in 43% of patients with chronic immune thrombocytopenic purpura with long-disease duration.

Flinn Sheds Light on Advances in MCL and Other Lymphomas

March 6th 2018

Ian W. Flinn, MD, PhD, discusses the impact of CAR T-cell therapy on the field of lymphoma and highlighted emerging options for the treatment of patients with MCL.

Myeloma Expert Provides Insight on Practice-Changing Data

March 2nd 2018

Jesus Berdeja, MD, provides an update on practice-changing data for the treatment of patients with multiple myeloma.

Flinn Highlights Emerging Combinations in CLL

February 26th 2018

Ian W. Flinn, MD, discusses ongoing advances with emerging combination regimens in chronic lymphocytic leukemia.

Ibrutinib Continues to Demonstrate Effectiveness in MCL

February 23rd 2018

Brad S. Kahl, MD, discusses the latest data for ibrutinib and highlights emerging treatments in mantle cell lymphoma.

Ramalingam Highlights Immunotherapy Advances in NSCLC

February 23rd 2018

Suresh A. Ramalingam, MD, discusses the exciting findings from the KEYNOTE-189 and IMpower150 immunotherapy trials in patients with non–small cell lung cancer.

Simon Shares Insight on Emerging Immunotherapy Regimens in NSCLC

February 21st 2018

George R. Simon, MD, discusses emerging advancements with immunotherapy combination strategies for patients with NSCLC.

Radiation Role Remains Uncertain in High-Risk Endometrial Cancer

February 20th 2018

David G. Mutch, MD, discusses questions surrounding the role of radiation therapy for patients with high-risk endometrial cancer.

ALK Inhibitors Continue to Reshape Treatment in NSCLC

February 20th 2018

Ravi Salgia, MD, PhD, discusses the evolving role of ALK-directed therapies for patients with non-small cell lung cancer.

Combinations Explored in MCL After Second BTK Inhibitor Approval

February 19th 2018

Brian T. Hill, MD, PhD, discusses acalabrutinib and ibrutinib’s efficacy in patients with mantle cell lymphoma and highlights emerging novel strategies in the treatment landscape.